Biogen Inc. is seeing a notable rise in its stock price, reflecting positive investor sentiment after strong quarterly results and growth in its product portfolio.
Biogen Inc. (NASDAQ:BIIB) is up today, with shares rising 1.13% to close at CA$230.17. This increase follows the company's impressive second-quarter earnings report, which highlighted a significant shift in its revenue generation strategy.
Advertisement
Biogen Inc
BIIB.US
BIIB.US
Biogen Inc
WealthAwesomeMarket cap
$33.63B
P/E
40.7x
52W high
$229.19
52W low
$136.94
1W change
+5.61%
Beta
0.17
Analyst Price Targets
Based on 37 analysts covering BIIB · as of Sep 21, 2026
Wall Street analysts forecast BIIB stock price to rise 4.6% over the next 12 months.
Consensus
Buy3.81 / 5.00
Avg. Target
C$238.18
+4.6% Upside
Previously C$237.19 on Sep 17, 2026
Current Price
C$227.60
Last close
Analyst Breakdown (37 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BIIB's historical volatility
30-Day Vol
28.2%
Annualized
90-Day Vol
37.9%
Annualized
Trend (90d)
+21.9%
Annualized drift
90d Mean
C$246.08
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$233.60 | C$211.97 – C$257.43 |
| 60 trading days | C$239.76 | C$208.98 – C$275.06 |
| 90 trading days | C$246.08 | C$207.97 – C$291.17 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are optimistic about Biogen's successful transition from legacy multiple sclerosis drugs to a more diverse growth portfolio, which is expected to drive future revenue and profitability.
Biogen's Growth Portfolio Generates $1.06 Billion in Q2 Revenues
The growth portfolio's revenue has increased by 24% year-over-year, surpassing the legacy MS portfolio for the first time, showcasing a significant shift in Biogen's business strategy.
Bull case
Biogen's growth products are now outpacing its legacy MS portfolio, indicating a successful transition that could lead to sustained revenue growth. The approval of new drugs and strong sales performance in the second quarter suggest a promising future.
Bear case
Despite the positive momentum, Biogen faces challenges from competition and pricing pressures in the pharmaceutical industry. Relying on a limited number of high-cost specialty drugs may pose risks to long-term growth.
Strong Q2 Earnings Drive Stock Performance
Advertisement
Biogen reported revenues of $2.74 billion for the second quarter, marking a 3.4% increase year-over-year and exceeding analysts' expectations by 12.1%. This performance was largely due to the success of its growth portfolio, which generated $1.06 billion in revenues, surpassing the legacy multiple sclerosis drugs for the first time.
Growth Products Outpacing Legacy Portfolio
The company's growth drugs, including Spinraza, Vumerity, and newly acquired products like Syfovre, have shown significant revenue increases. For instance, revenues from Skyclarys rose 29% to $168 million, while Zurzuvae revenues surged by 53% to $71 million, indicating a successful transition in Biogen's product strategy.
Future Outlook Remains Positive
With the ongoing rollout of new therapies and the approval of innovative treatments like the at-home LEQEMBI Pen, Biogen is well-positioned for continued growth. Analysts suggest that the company's ability to expand its product offerings and improve accessibility could further enhance its market position in the coming years.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
